OncoMatch/Clinical Trials/NCT05657873
A Study of Targeted Radiation Therapy in People With Non-Small Cell Lung Cancer (NSCLC)
Is NCT05657873 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Anti-PD-(L)1 based immunotherapy and Platinum based chemotherapy for non small cell lung cancer.
Treatment: Anti-PD-(L)1 based immunotherapy · Platinum based chemotherapy — The purpose of this study is to see whether adding liver stereotactic ablative radiotherapy/L-SABR to standard drug therapy is better than standard drug therapy alone for people with metastatic non-small cell lung cancer/NSCLC.
Check if I qualifyExtracted eligibility criteria
Cancer type
Small Cell Lung Cancer
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: ALK wild-type
Required: BRAF wild-type
Required: EGFR wild-type
Required: ROS1 wild-type
Disease stage
Required: Stage IV
Metastatic disease required
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: anti-PD-(L)1 therapy — first-line metastatic
the planned anti-PD-(L)1-based regimen represents first-line systemic therapy in the metastatic setting
Cannot have received: external beam radiation therapy to the liver
prior external beam radiation therapy to the liver
Lab requirements
Liver function
total bilirubin ≤ 1.5 x uln; ast/ alt ≤ 5 x uln
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- BAPTIST ALLIANCE - MCI (Data Collection Only) · Miami, Florida
- Memorial Sloan Kettering at Basking Ridge (All Protocol Activities) · Basking Ridge, New Jersey
- Memorial Sloan Kettering Monmouth (All Protocol Activities) · Middletown, New Jersey
- Memorial Sloan Kettering Bergen (All protocol activities) · Montvale, New Jersey
- Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities) · Commack, New York
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify